Access to PCSK9 Inhibitors

Journal article

Open access

Peer reviewed

Seth J Baum, Norman E Lepor and Jennifer G Robinson

Reviews in cardiovascular medicine, Vol.19(S1), pp.S47-S50

2018

DOI: 10.3909/ricm19S1S0006

PMID: 30207557

Files and links (1)

url

https://doi.org/10.3909/ricm19S1S0006View

Published (Version of record) Open Access

no abstract

Dyslipidemias - drug therapy

Humans

Antibodies, Monoclonal - therapeutic use

Treatment Outcome

Serine Proteinase Inhibitors - supply & distribution

Biomarkers - blood

Proprotein Convertase 9 - metabolism

Evidence-Based Medicine

Anticholesteremic Agents - supply & distribution

Dyslipidemias - enzymology

Patient Selection

Serine Proteinase Inhibitors - therapeutic use

Dyslipidemias - blood

Anticholesteremic Agents - therapeutic use

Proprotein Convertase 9 - antagonists & inhibitors

Health Services Accessibility

Clinical Decision-Making

Cholesterol, LDL - blood

Dyslipidemias - diagnosis

Title: Subtitle: Access to PCSK9 Inhibitors
Creators: Seth J Baum - Preventive Cardiology, Inc., Boca Raton, FL
Norman E Lepor - Cedars-Sinai Heart Institute, Los Angeles, CA
Jennifer G Robinson - Departments of Epidemiology & Medicine, University of Iowa College of Public Health and Carver College of Medicine, Iowa City, IA
Resource Type: Journal article
Publication Details: Reviews in cardiovascular medicine, Vol.19(S1), pp.S47-S50
DOI: 10.3909/ricm19S1S0006
PMID: 30207557
NLM abbreviation: Rev Cardiovasc Med
ISSN: 1530-6550
eISSN: 2153-8174
Publisher: United States
Language: English
Date published: 2018
Academic Unit: Epidemiology; Internal Medicine
Record Identifier: 9983995014302771

36 Record Views